HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Kitchlu A, Luo B, Jeyakumar N, et al.

CKD Prevalence, Patterns of Treatment, and Outcomes in Patients with Cancer: A Population-Based Cohort Study

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:11A 2020

BACKGROUND

Chronic kidney disease (CKD) may impede optimal cancer treatment and result in worse outcomes. There are limited data to assess receipt of systemic therapy, radiation therapy, and palliative care in patients with cancer and CKD.

METHODS

We conducted a population -based cohort study of all patients (≥18 years old) with a new cancer diagnosis in Ontario, Canada (2007-2015). We categorized patients according to CKD status at cancer diagnosis [estimated glomerular filtration rate (eGFR) ≥60 (referent group), 45-59, 30-44, 15-29, <15 mL/min/1.73m2, dialysis and transplant recipients]. We used multivariable Fine and Gray proportional hazards models to assess overall survival, receipt of systemic therapy, radiation and palliative care (6- months prior to death) in the 5 most common solid cancers (bladder, breast, colon, prostate, lung) and kidney cancer.

RESULTS

We identified 128,489 patients with a new cancer diagnosis, of whom 16% had pre-existing CKD (eGFR <60 mL/min/1.73m2). Patients with the 6 cancers of interest accounted for 73% (93,751). Kidney function at cancer diagnosis was associated with (progressively) worse overall survival in CKD stages 3a-5, dialysis, and transplant recipients (Figure a). Increasing CKD stage was associated with significantly reduced receipt of all treatment modalities [systemic therapy, radiation and palliative care (Figure b-d)]. Patients receiving dialysis had 2-fold increased mortality in bladder, breast and colon cancers, and 3-fold mortality in kidney cancers.

CONCLUSION

In patients with cancer, CKD is associated with reduced exposure to systemic, radiation and palliative treatments and worse overall survival. Strategies to improve cancer care in the CKD population are needed.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.